DAE HWA Pharmaceutical (A067080) Stock Overview
A pharmaceutical company, produces and supplies pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 1/6 |
A067080 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
DAE HWA Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,770.00 |
| 52 Week High | ₩24,900.00 |
| 52 Week Low | ₩8,690.00 |
| Beta | -0.16 |
| 1 Month Change | -30.56% |
| 3 Month Change | -39.18% |
| 1 Year Change | -38.67% |
| 3 Year Change | -2.88% |
| 5 Year Change | -35.04% |
| Change since IPO | 242.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| A067080 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -14.2% | -8.3% | -7.4% |
| 1Y | -38.7% | -3.7% | 157.5% |
Return vs Industry: A067080 underperformed the KR Pharmaceuticals industry which returned 1.2% over the past year.
Return vs Market: A067080 underperformed the KR Market which returned 171% over the past year.
Price Volatility
| A067080 volatility | |
|---|---|
| A067080 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A067080 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A067080's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Kim Eun-Seok | www.dhpharm.co.kr |
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthritis, gastro-intestinal, obesity, antispasmodic, diabetics, hypertension, hyperlipemia, antithrombotic and anticoagulant, hepatic, erectile dysfunction, urinary incontinence, prostatic hyperplasia, pregnancy, bug bite, anthelmintics, and cosmetic care, as well as vitamins and minerals, tonics, nutrition products. It also provides transdermal drug delivery system, a pharmaceutical preparation that is applied to the intact skin for systemic absorption; and active pharmaceutical ingredients.
DAE HWA Pharmaceutical Co., Ltd. Fundamentals Summary
| A067080 fundamental statistics | |
|---|---|
| Market cap | ₩153.62b |
| Earnings (TTM) | ₩1.82b |
| Revenue (TTM) | ₩143.42b |
Is A067080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A067080 income statement (TTM) | |
|---|---|
| Revenue | ₩143.42b |
| Cost of Revenue | ₩95.82b |
| Gross Profit | ₩47.60b |
| Other Expenses | ₩45.78b |
| Earnings | ₩1.82b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 104.00 |
| Gross Margin | 33.19% |
| Net Profit Margin | 1.27% |
| Debt/Equity Ratio | 118.7% |
How did A067080 perform over the long term?
See historical performance and comparisonDividends
Does A067080 pay a reliable dividends?
See A067080 dividend history and benchmarks| DAE HWA Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Jun 29 2026 |
| Dividend Pay Date | Aug 26 2026 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 59 days |
Does A067080 pay a reliable dividends?
See A067080 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/27 18:56 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DAE HWA Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.